Tag: Dana-Farber Boston Children’s Cancer and Blood Disorders Center

Antibody Treatment Prevents Graft Versus Host Disease, a Major Bone Marrow Transplant Complication, in Advanced Preclinical Tests

sarah JonasResearch Results

An experimental antibody treatment largely prevented a bone marrow transplant complication called graft versus host disease (GVHD) in the intestines, without causing broad immune suppression, in a preclinical study led by researchers from Penn Medicine and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and published today in Science Translational Medicine.

New immunotherapy target discovered for malignant brain tumors

sarah JonasResearch Results

Scientists say they have discovered a potential new target for immunotherapy of malignant brain tumors, which so far have resisted the ground-breaking cancer treatment based on harnessing the body’s immune system. The discovery, reported in the journal CELL, emerged from laboratory experiments and has no immediate implications for treating patients.